BX LAB TECHNICAL ARTICLE
Novartis Paid $12 Billion for Avidity. The Structure Is the Interesting Part.
The price says AOCs arrived. The carve-out says something more specific about where the platform is worth owning.
Key takeaways
Novartis closed the acquisition on 27 February 2026 at $72 per share, about $12bn.
Early-stage precision cardiology was carved out into a separate listed company before the deal closed.
SpinCo keeps platform rights in cardiology only, plus the Bristol Myers Squibb and Lilly collaborations.
What happened
On 26 October 2025 Novartis agreed to buy Avidity Biosciences for $72 per share in cash, valuing the company at roughly $12 billion fully diluted — a premium of about 46% over the previous close. The deal completed on 27 February 2026. What Novartis bought was Avidity muscle-directed Antibody Oligonucleotide Conjugate platform and three late-stage programmes: Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1. At the time it was the second largest pharmaceutical acquisition of the year, behind the Johnson & Johnson purchase of Intra-Cellular Therapies.
The price is not the news
A large acquirer paying a large premium for a late-stage asset is ordinary. What is worth reading closely is that the deal was not a clean purchase of a company. Before closing, Avidity separated its early-stage precision cardiology programmes into a new listed company, SpinCo, led by Kathleen Gallagher, previously Avidity chief programme officer, with Sarah Boyce as chair. AOC 1086 and AOC 1072 — targeting phospholamban and PRKAG2 cardiomyopathies — went with it.
Read the rights split carefully
The easy summary is that SpinCo kept the AOC platform. That is not what the terms say. SpinCo holds rights to continue developing the platform, including next-generation improvements, for applications in the cardiology field. The muscle-directed platform and the late-stage programmes went to Novartis. SpinCo also took the Bristol Myers Squibb and Eli Lilly collaborations, the BMS one covering up to five cardiovascular targets on the AOC platform. So the same chemistry now sits inside two companies, partitioned by tissue rather than by technology.
Why a buyer would want it that way
Novartis paid for three programmes that are close to filing and for the delivery chemistry that makes them work in muscle. Early cardiology assets would have added risk and dilution to that thesis without adding to it. Splitting them out let Novartis buy the part it could price and left the part it could not with people who believe in it and with two partners already funding it. That is a reasonable reading; it is also a reading, not a disclosure. Neither company has explained the logic in those terms.
What it means for the chemistry supply chain
An AOC is an antibody, a linker and an oligonucleotide. The antibody is biology. The oligonucleotide and the linker are chemistry — a chemically modified oligonucleotide built from phosphoramidites, joined by a linker that has to survive circulation and release its payload inside the cell. When a modality moves from platform bet to a $12bn late-stage asset, demand for those chemical inputs stops being exploratory and starts being a supply commitment with a filing date attached. Three late-stage programmes at one company, plus five cardiovascular targets at another, is a lot of oligonucleotide and a lot of linker.
The honest caveat
None of this makes AOCs a solved problem. The conjugation chemistry, the therapeutic index and the manufacturability of an antibody-oligonucleotide conjugate at commercial scale are all still being worked out in public. What the deal establishes is narrower and still significant: a large pharmaceutical company was willing to pay $12 billion on the assumption that they will work, and to restructure a target company to get the part it wanted. For anyone supplying into this chain, that is the signal worth acting on — not the number.
Turn the product name into a decision-ready specification
A purchasing name is only the starting point for a research material. Build the specification around exact chemical identity, form and assay basis. Define how identity will be confirmed and distinguish chromatographic purity from assay, concentration or active-content measurements. Add the attributes that could alter use, such as water, residual solvent, counterion, residual metals, known related substances or storage sensitivity. Acceptance limits should reflect the intended function rather than copying every available analytical result into a specification. Where a method is critical, record the technique, column or detection principle and sample preparation assumptions. This gives chemistry, analytical and procurement teams one shared definition of the material and reduces the chance that a technically correct but operationally unsuitable lot enters the project.
Qualify the material in the workflow that matters
A CoA can establish lot results against an agreed specification, but it cannot by itself prove performance in the intended research workflow. Plan a small, controlled qualification using a representative substrate, sequence, enzyme, reaction or analytical method. Include a suitable reference or previously accepted lot when available, keep preparation conditions comparable and predefine the observations that will trigger acceptance or investigation. Useful endpoints can include conversion, coupling efficiency, impurity formation, recovery, transcript integrity, conjugation yield or downstream signal, depending on the material. Record both the chemical result and practical behavior such as dissolution time, foaming, color change, precipitation or instrument delivery. This separates a material-quality question from a process-compatibility question and creates evidence that can support later lot-to-lot comparison.
Review process and scale risks before increasing quantity
Scale changes can expose risks that are not visible in a small research batch. For a research material, review handling, purification, analysis and scale-up before committing to a larger campaign. Estimate concentration, heat and mass-transfer needs, hold times, mixing limits, filtration area and the stability window of intermediates or prepared solutions. Identify the operations that control impurity rejection rather than assuming reaction yield alone will predict an acceptable isolated product. Raw-material availability and variability should be included in the route review, especially when a protecting-group reagent, specialty precursor or purification medium has a long lead time. A staged plan—feasibility, confirmation batch and then larger manufacture—provides checkpoints for analytical comparability, safety review and yield reconciliation while there is still room to adjust the process.
Build an analytical package that answers buyer questions
The useful documentation package should connect identity, purity and intended use. At minimum, align the specification and lot-specific Certificate of Analysis; then identify which supporting data are appropriate for the chemistry, such as HPLC or UPLC, LC-MS, high-resolution MS, NMR, water, residual solvents or inorganic-ion analysis. Chromatograms and spectra are most helpful when the material form, sample preparation and acceptance logic are clear. For complex or highly polar materials, a single percentage may not describe all relevant attributes, so note whether the result represents area purity, assay, concentration or another basis. Change control should cover shifts in route, critical starting material, purification approach, analytical method or manufacturing site when those changes could affect comparability. This framework helps technical, QA and procurement reviewers reach the same conclusion from the same evidence.
Use a structured request to shorten technical review
A complete inquiry for a research material should include the structure or unambiguous identifier, desired form, target quantity, expected future scale, intended use, target date and required documentation. Add known constraints: sensitive functional groups, prohibited solvents, metal limits, water sensitivity, shipping temperature, packaging preference or compatibility with an established method. If the request supports a regulatory submission, state the development stage and the documents expected, but do not assume that research-use or non-GMP material carries a qualification it does not have. Ask the supplier to identify open assumptions in the quotation and to separate confirmed specification items from values that still require method development. The resulting technical exchange is more efficient, and the final quotation can be tied to a material definition that is meaningful to scientists, procurement and quality reviewers.
Build a fit-for-purpose request
Before sourcing or scale-up, align the exact structure, intended workflow, target purity and assay basis, required form, storage conditions, quantity, timeline and documentation. If a catalog item does not match those requirements, a related analog, impurity standard, reference material or research-use custom route can be reviewed.
References
Technical context is supported by the peer-reviewed literature below.
- Novartis (27 February 2026) Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- Avidity Biosciences (26 October 2025) Avidity Biosciences enters into agreement to be acquired by Novartis AG — includes the SpinCo separation terms
- Avidity Biosciences (2024) Expansion of cardiovascular collaboration with Bristol Myers Squibb for up to five targets using the AOC platform
- Drug Discovery World (November 2025) Novartis acquires Avidity Biosciences for $12 billion